logo
Share SHARE
FONT-SIZE Plus   Neg

Icon Bioscience Names David Tierney President & CEO - Quick Facts

Icon Bioscience Inc., a privately held specialty biopharmaceutical company focused on the development and commercialization of unique ophthalmic pharmaceuticals based on its patented and proprietary Verisome drug delivery technology, said that David Tierney joined the Company as President & Chief Executive Officer.

Previously, Tierney served as President & COO of Oceana Therapeutics, Inc., a specialty therapeutic company he co-founded in mid-2008. Oceana quickly established a global commercial network and by December 2011 was acquired by Salix Pharmaceuticals (SLXP).

In 2000, David was appointed President & CEO of Hydro Med Sciences (HMS), a research firm with a promising drug delivery platform. Under his leadership, HMS emerged as Valera Pharmaceuticals, a fully integrated, commercial, specialty pharma company that successfully completed an initial public offering in 2005. Valera has since been merged into Endo Pharmaceuticals (ENDP). Prior to Valera, Tierney was President of Biovail Technologies, a drug delivery division of Biovail Corporation - a predecessor to Valeant Pharmaceuticals International (VRX). Earlier in his career, he served as Senior VP, Drug Development at Roberts Pharmaceutical and in a variety of management positions at Elan Corporation.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Amgen reported an increase in second-quarter profit, driven by sales of arthritis drug Enbrel and osteoporosis treatments Xgeva and Prolia, and improved margins. Both earnings and sales topped Wall Street estimates. Electronic Arts Inc. (EA) on Thursday reported an increase in profit for the first quarter, reflecting continued strong digital revenues, with both earnings and revenues topping Wall Street estimates. However, shares of the company fell over 4 percent, after having detailed a weak outlook. Redwood... LinkedIn Corp., the world's largest online professional network, said Thursday after the markets closed that its second quarter loss widened sharply from last year, as higher costs and expenses more than offset a 33% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in well above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
Follow RTT